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Abstract
Colorectal cancer accounts for 8% of all cancer deaths and can be prevented through timely
removal of colon polyps. Despite recommendations for routine screening, approximately 31.2%
of patients go unscreened for this disease (Centers for Disease Control and Prevention, 2018).
The purpose of this project was to determine screening rates and documentation mechanisms for
colorectal cancer in an urban primary care practice, to determine how many patients completed
the screening, and to present findings to the practice providers along with exploring ways to
increase screenings. An additional purpose of this project was to determine and identify patient
demographics which can impact rates of screening. A retrospective chart review was conducted
of patients aged 50 to 75 years old in an urban primary care clinic from January 1, 2019 to March
31, 2019. Charts were reviewed to determine if colorectal cancer screening was recommended
and documented per screening guidelines and whether patients completed the screening. Overall
rate of screening was 61%, which did not meet the national goal but was within the meaningful
use measures. Of the 120 charts reviewed, 72 patients had completed colorectal cancer
screening. There were no significant differences within demographic variables and provider
screening rates. Results from the chart review were then presented via focus group to two
providers from the clinic. Three strategies were discussed during the meeting: delegating a clinic
support staff to identify scheduled patients who need screening, having the provider document
when screening is due on the patient’s problem list, and adding an alert on the patient
“dashboard” to provide an immediate alert when screening is due. Race, gender, location of
residence, and provider type did not yield statistical difference in screening rate. Future benefit
may be seen by repeating the chart review now that the information has been presented to
providers and specific strategies are being planned.
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Evaluating Colorectal Cancer Screening Rates in an Urban Primary Care Practice
Introduction and Background
Colorectal cancer is a significant health concern affecting approximately 4% of American
adults each year (American Cancer Society, 2017). Unfortunately, despite available screening
options for early detection and treatment, only 50 to 75% of eligible patients are screened
(Triantafillidis, Vagianos, Gikas, Korontzi, & Papalois, 2017). Researchers have identified
multiple barriers to colorectal cancer screening, including lack of resources, lack of education,
cost, and negative past screening experiences (Wang et al., 2017). Without addressing ways to
increase colorectal cancer screening rates, late diagnosis, death, and significant health expenses
related to colorectal cancer will continue. The purpose of this DNP project was to determine
screening rates and documentation mechanisms for colorectal cancer in an urban primary care
practice and to facilitate a conversation with clinic providers on ways to increase screening rates.
Colorectal cancer is the irrepressible division of abnormal cells in the colon or rectum
resulting in a malignant tumor, usually over a 10 to 20-year period (National Cancer Institute,
2016). From 2007 to 2013 in the United States, there were 40.1 new cases of colorectal cancer
per 1,000 people (Centers for Disease Control and Prevention, 2017). Kentucky has one of the
highest rates of colorectal cancer in the nation, with 49.4 per 1,000 new cases in 2014 (Kentucky
Department of Public Health, 2016). In addition to high incidence rates, Kentucky also had one
of the highest mortality rates from colorectal cancer from 2009 to 2014. During this time period
the mortality rate of colorectal cancer for males in Kentucky was 20.3 to 23.7 per 100,000
people, and 13.0 to 14.2 per 100,000 for females. Despite these statistics, in 2014 Kentucky
ranked 24th in the nation in screening rates. As of 2019, only 67.6% of people in Kentucky from
ages 50 to 75 have undergone colorectal cancer screening (American Cancer Society, 2019).
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The risk of colorectal cancer varies based on race and gender. Nationally, men are at greater
risk for colorectal cancer than women, with risk increasing with age group (Centers for Disease
Control and Prevention, 2017). In the mid 1980s the incidence of colorectal cancer was similar
for both black and Caucasian patients. However, the incidence has gradually declined for the
Caucasian population while remaining steady among African Americans causing African
Americans to have the highest incidence of colorectal cancer in comparison to other ethnicities
(Centers for Disease Control and Prevention, 2017). While the reason for this is not completely
understood, access to care and genetic differences are thought to contribute to increased
incidence of colorectal cancer in the African American population.
The cost of colorectal cancer screening varies depending on the strategy used to screen
patients. In 2016 the average cost of a colonoscopy ranged from $2,300 to $5,100 while the cost
of a FIT test ranged from $130.00 to $530.00. Although, completion of colorectal cancer
screening does come at a cost, all recommended colorectal cancer screening strategies are less
costly than the treatment of colorectal cancer (Patel & Kilgore, 2015). In 2010, an estimated $14
billion went to the direct costs of colorectal cancer care in the United States (Centers for Disease
Control and Prevention, 2011). Moreover, the cost of inpatient treatment for colorectal cancer in
the state of Kentucky increased from $80 million in 2006 to $110 million in 2012 (American
Cancer Society, 2019).
MACRA
The Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) is a legislative act
which changes reimbursement for providers who care for Medicare beneficiaries (Department of
Health and Human Services, 2019). This program was created to shift the focus of
reimbursement to quality and value of care rather than volume. Under this act, providers are
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reimbursed based on the quality and effectiveness of their care rather than the previous fee for
service system. Providers earn more or less depending on their performance against these
measures of quality and efficiency (Department of Health and Human Services, 2019).
Patient completion of a colorectal cancer screening test is one of the clinical quality measures
established through MACRA. For this measure, provider reimbursement is based on the rate that
patients complete colorectal cancer screening, not just if the screening test was ordered
(Department of Health and Human Service, 2019). The rate is determined by dividing the
number of patients who have completed colorectal cancer screening by the total number of
eligible patients who were seen within the performance period. This measure is to be submitted
to the Department of Health and Human Services at least once per 12-month performance period
for patients seen during that time frame (Department of Health and Human Services, 2019).
Pledge to Screen
The National Colorectal Cancer Roundtable (NCCRT) created the “80% Pledge,” a national
initiative with the goal that 80% of all patients age 50 to 75 years of age are routinely screened
for colorectal cancer (National Colorectal Cancer Roundtable, 2019). The original initiative was
created in 2014 and set a four-year time span for achievement. In 2014, the national screening
rate was 66.2%. While the goal was not achieved by 2018, over 1,500 organizations continue to
work towards achievement of the target. Organizations from all 50 states, Puerto Rico and Guam
have signed the pledge to work towards achieving this 80% goal (National Colorectal Cancer
Roundtable, 2019).
The purpose of this project was to determine screening rates and documentation mechanisms
for colorectal cancer in an urban primary care practice, to determine how many patients
completed the screening, and to present findings to the practice providers along with exploring
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ways to increase screenings. An additional purpose of this project was to determine and identify
patient demographics which can impact rates of screening. Information would then be presented
to providers in order increase their knowledge surrounding colorectal cancer and develop
strategies to increase rates of colorectal cancer screening. The specific aims were to determine
current rates of providers ordering colorectal cancer screening tests; determine rate of patients
completing colorectal cancer screening tests; determine how colorectal cancer assessment is
documented by providers in an urban primary care practice; determine rates of MACRA
documentation compliance; and present findings from chart review to providers to enable a
conversation about potential changes to increase rates of colorectal cancer screening.
Theoretical Model
The theoretical model guiding this project was Pender’s Health Promotion Model (Pender,
2011). This model focuses on changing unhealthy behaviors to healthy behaviors. The model
defines health as a “positive dynamic state” and not just the lack of disease. There are three areas
of focus associated with the model: individual characteristics and experiences, behavior specific
cognitions and affect, and behavioral outcomes. The model acknowledges health professionals as
a component of the interpersonal environment along with families and friends (Pender, 2011). As
part of this environment, health care professionals have the ability to influence the behavior of
the patient and increase or decrease the likelihood of the patient taking part in health-promoting
behavior. The idea that patients are more likely to complete health promoting activities when
they receive support from others— along with positive reinforcement surrounding the positive
health choice—reflects the focus areas in Pender’s Health Promotion Model (Pender, 2011).
This model helps providers understand the completion of colorectal cancer screening as a
health promotion behavior. This project focused on determining whether or not demographic
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variables impact the likelihood of completing colorectal cancer screening. Demographic
variables of patients including age, race and location of residence were evaluated to determine
how rates of colorectal cancer screening in an urban primary care clinic vary among differing
physiological and biological backgrounds (Pender, 2011). In addition, whether or not the
provider, identified as an interpersonal influence, had recommended colorectal cancer screening
to the patient was also reviewed.
Review of Literature
Screening Methods
Evidence shows that there are multiple ways to screen for colorectal cancer. Recommended
screening methods include colonoscopy, Fecal Immunochemical Test (FIT), flexible
sigmoidoscopy, CT Colonography, hemoccult sensa, and Fecal DNA (Centers for Disease
Control and Prevention, 2019). The patient and provider should discuss these screening options
along with patient risk and comorbidities to determine which test is most appropriate for the
patient. There is varying degree of sensitivity and specificity for each of these tests (Centers for
Disease Control and Prevention, 2019).
Colonoscopy is the preferred method for screening starting at age 50 for all average risk and
high-risk patients (Centers for Disease Control and Prevention, 2019). It has a sensitivity of 95%
and specificity of 86%. If the colonoscopy is normal, it should be repeated every ten years. This
procedure allows for both detection and prevention, as it provides visualization of the entire
colon and allows for removal of polyps or precancerous lesions during the procedure (Rex et al.,
2017).
Stool testing is also available. The FIT test can be used in place of colonoscopy for detection
of colorectal cancer. This test should be performed annually, and a positive result should be
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followed by colonoscopy (Rex et al., 2017). FIT testing is the only non-invasive test to be
considered a tier 1 screening test. The sensitivity of this is 73.8% and the specificity is 96.4%
(Rex et al., 2017).
Flexible sigmoidoscopy, CT Colonography, and Fecal DNA testing are considered tier 2 tests
(Rex et al., 2017). Flexible Sigmoidoscopy is a prevention test which should be performed every
five to ten years and has a sensitivity of 95% and specificity of 87% (Rex et al., 2017). The CT
Colonography, also referred to as a virtual colonoscopy, can only be used as a detection test and
should be completed every five years. This has a sensitivity of 84% and a specificity of 88%
(Rex et al., 2017). Fecal DNA testing is another detection test and should be completed every 3
years. It has a sensitivity of 92% and a specificity of 87% (Rex et al., 2017). Hemoccult sensa,
which is a detection test, should be completed annually and has a sensitivity of 84% and
specificity of 88% (Rex et al., 2017). A positive result on a test used for colorectal cancer
detection should be followed by colonoscopy.
Screening Guidelines
Colorectal mortality can be decreased with recommended screening. Levin et al. (2018) have
projected that by increasing the national rate of colorectal cancer screening to over 80%, the
death rate associated with this type of cancer would drop to less than 19%. The United States
Preventative Services Task Force (USPSTF) recommends screening for average risk individuals
to begin at age 50 and continue until age 75 (Rex et al., 2017). For patients 75 to 85 years old,
screening should be provided on a case by case basis while considering the current health status
of the patient. For those over the age of 85 screening is no longer recommended (Rex et al.,
2017).
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Recommendations for screening vary according known to risk factors. Those with increased
risk of developing colorectal cancer should be screened earlier and more frequently than patients
of average risk (U.S. Preventative Services Task Force, 2017). Patients are considered high risk
if they have a personal history of colorectal cancer, a history of adenomatous polyp (an advanced
polyp is defined as an adenoma which is either 1 cm or larger, has high grade dysplasia, is an
advanced serrated lesion or sessile serrated polyp with cytologic dysplasia), or inflammatory
bowel disease.
There are other non-modifiable risks such as age, gender, race and family history which can
increase the chance of developing colorectal cancer (American Cancer Society, 2017). While
colorectal cancer can occur at any age, it is uncommon prior to the age of 40 and risk increases
with age (Centers for Disease Control and Prevention, 2018). Regardless of race, colorectal
cancer is more prevalent in males than females (Centers for Disease Control and Prevention,
2018).
In terms of race, the USPSTF recommends that screening for African Americans start at age
45 due to increased rates of colorectal cancer among the African American population (BibbinsDomingo et al., 2016). Unfortunately, regardless of race, Medicaid does not provide
reimbursement for colorectal cancer screening until age 50 (Rex et al., 2017). In the African
American population most instances of colorectal cancer occur after the age of 60.
Having a family member who has had colorectal cancer or advanced adenomatous polyp or a
family member with known genetic syndromes that cause colorectal cancer also increases risk
for colorectal cancer (Rex et al., 2017). Patients should be screened starting at age 40 or 10 years
younger than their earliest diagnosed family member if they have first degree relative with colon
cancer or adenomatous polyps diagnosed before age 60 or two first degree relatives with colon
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cancer or adenomatous polyp at any age. A first degree relative is considered parents, children,
and siblings. Screening should be repeated in these patients every five years (Rex et al.,
2017). People with a first-degree relative with colon cancer or adenomatous polyp diagnosed at
60 years of age or older or two second degree relatives, such as aunts, uncles and grandparents,
with colorectal cancer should begin screening at age 40 and be advised to be screened as average
risk persons (Rex et al., 2017).
There are modifiable risk factors as well. For example, maintaining healthy weight and
regular physical activity can reduce the risk of type II diabetes which is associated with higher
rates of colorectal cancer (American Cancer Society, 2017). Patients who regularly exercise,
maintain a healthy weight and avoid moderate to heavy use of alcohol have a lower risk of
developing colorectal cancer (American Cancer Society, 2017). Boyle et al. (2012) reported that
being physically active can decrease the risk 25% (physically active was defined as recreational,
household, or occupational physical activity). Obesity has also been identified as a risk for
developing colon cancer. Obese men have a 50% higher risk of developing colon cancer and a
20% higher risk of developing rectal cancer. Obese women have a 20% higher risk of developing
colon cancer and a 10% higher risk of developing rectal cancer than those of normal weight.
Additionally, moderate to heavy use of alcohol can increase the risk of colorectal cancer by 20 to
40% compared to non-drinkers and occasional drinkers (Boyle et al., 2012).
Facilitators to Screening
The use of quality improvement activities can help to facilitate provider ordering and patient
completion of colorectal cancer screening. A significant factor is the recommendation by a
provider to the patient. In fact, patient and provider communication can increase screening rates
by 20% (Knight et al., 2015). In addition, several mechanisms to facilitate colorectal cancer
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screening and aid the provider in making an appropriate screening recommendation are
associated with electronic medical records. Research has shown that implementation of an EMR
alert system increases colorectal cancer screening rates (Guiriguet et al., 2016). Use of
continuing medical education and implementation of a clinic facilitator to improve the ordering
process for testing have also been found to increase screening rates (Weiner et al., 2017).
Researchers have also examined ways to increase rates of patient compliance to colorectal
cancer screening. For example, live phone call reminders to encourage patients to complete the
ordered screening and mail in options for screening have both been shown to increase patient
compliance (Ylitalo et al., 2019). Allowing patients to complete fecal DNA testing in their
homes eliminates the barrier of transportation, need for completion of bowel preparation, and
fear of the procedure which have all previously been shown as barriers to screening (Ylitalo et
al., 2019).
Barriers to Screening
Primary care providers have identified several barriers at the system level which impede the
recommending and ordering of screening tests. Providers have found that there is a lack of
screening resources and a lack of (or difficulty using) systems to identify patients appropriate for
screening. They also reported a lack of support staff for follow up and lack of time to discuss
screening and patient questions (American Cancer Society, 2017).
Patients have identified multiple barriers to completing colorectal cancer screening tests. Most
often cited are cost associated with screening, negative screening experiences in the past, lack of
education regarding the importance of completing screening tests, fear of cancer diagnosis, and
lack of resources such as transportation (Knight et al., 2015). In Kentucky, patients reported in a
2008 survey that the main barrier to colorectal cancer screening was a belief that there was no
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need to have this completed (Knight et al., 2015). Cost associated with colorectal cancer
screening continues to be a barrier. Testing should be covered at no cost for patients with
insurance. However, if a screening test yields abnormal results, this may result in further testing,
biopsies, or polypectomy, and insurance may consider this follow up testing to be diagnostic
rather than preventative screening. In this case the patient may be charged 20% of the insurance
cost and/or a co-pay (American Cancer Society, 2019).
Methods
This project was completed at an urban primary care clinic in Lexington, Kentucky. The
mission of the clinic is to provide “health care with compassion for Lexington's Northside and
urban community” (UK Healthcare, 2020). The target population is the providers who work in
the clinic and the patients who are seen there for whom colorectal cancer screening is indicated.
This project is congruent with the mission of this clinic as improving provider knowledge
increases quality of care provided. Stakeholders include clinic physicians, clinic nurse
practitioners, the clinic manager, and patients and their families. Three of the providers are
physicians while three of the providers are nurse practitioners.
Permission for this study was obtained through the University of Kentucky Institutional
Review Board. A retrospective chart review was conducted assessing colorectal cancer provider
screening rates of patients from January 1, 2019 to March 31, 2019. All data were deidentified using a crosswalk table. A study number was assigned to each patient and kept
separate from the data. Inclusion criteria for this project included patients aged 50 to 75 years old
who were seen in the primary care clinic during the selected time period. All charts of patients
not meeting the criteria were excluded. A list of patients meeting these criteria were provided to
the primary investigator from the clinic manager. From the list of 392 patients, 20 patients were
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randomly selected from each of the 6 providers for a total of 120 patients. See Appendix 1 for
the list of variables used in the chart review.
Cross sectional data were collected on each of the 120 subjects. Demographic data included
patient age, gender, race, and place of residence. In order to analyze screening processes, charts
were reviewed to determine whether or not screening was recommended by the provider, the
incidence of patient completion of diagnostic screening, the method of diagnostic screening each
patient completed, and completion of documentation required to meet MACRA compliance.
Charts were also reviewed to determine if colorectal cancer screening had been recommended by
the provider to patients who had not completed testing. If testing was recommended but not
completed, charts were reviewed to determine if the reason this had not been completed was
documented.
After data were collected, a study number was assigned to each patient that was cross walked
to the results without any identifying data. The cross-walk table was kept separate from the
results. The results were reported in aggregate form and kept on a password protected University
of Kentucky computer where data will be stored for seven years. All electronic data files will be
deleted according to the University of Kentucky's policy on destruction of electronic records.
Means and standard deviation were used to analyze demographic data. Rates of completion of
colorectal cancer testing by gender, race and location were analyzed using Pearson’s chi-squared
analysis to determine statistical significance. Provider screening rates were compared both
individually and grouped by provider type. Pearson’s chi-squared analysis was used to determine
difference in screening rates for individual provider and provider type. Data analysis was
completed using SPSS Version 26 Analysis with an Alpha Value of 0.05 for all analyzed data.
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A meeting was scheduled with the six primary care providers from the clinic. Two of the
providers attended the meeting. The current ACG guidelines and recommendations for colorectal
cancer screening were reviewed and barriers to screening completion were explored. Providers
were presented with the findings from the chart audit and presented with their individual
screening rates. Strategies to improve documentation of completed screening were discussed.
Results
Of the 120 charts reviewed, the majority were female (n=72, 60%). The age range was 50 to
74 years with a mean age of 58.9 years. The majority of the patients (n = 106, 88.3%) lived in
Lexington. Ethnicity was equally distributed between Caucasian and Black patients (n = 58,
48.3%; n = 55, 45.83%). Only seven patients were identified as Hispanic.
Completed colorectal cancer screening was found in 61% of patients. Among male patients,
67% had completed colorectal cancer screening, compared with 57% of females. There were no
significant differences between gender, race, and location of residency and colorectal cancer
screening rates. Calculated p-values using Pearson’s chi-squared were .285, .790 and .288,
respectively.
Screening rates for colorectal cancer per provider were assessed and ranged from 45% to 75%.
There were no statistical differences when comparing screening rates among providers (c = pvalue of .344). Charts were also evaluated to determine the rate at which colorectal screening
completion was documented to meet MACRA compliance. Documentation of screening ranged
from 35% to 60%. Screening rates showed that 65% patients who were seen by physicians had
completed colorectal cancer screening, while 57% of patients who were seen by nurse
practitioners were screened. The p-value was .350, which failed to show statistical difference in
the two groups of screening rates.
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Completion of colorectal cancer screening was documented in four different locations of the
EMR. In order to meet MACRA compliance, documentation must be completed in a way to
populate in the EMR Dashboard. This occurs when a colonoscopy is completed within the
facility or if the provider manually documents completion of colorectal cancer screening. Of the
73 patients who completed colorectal cancer screening, completion of testing for 56 patients was
documented within the results section of the EMR. However, 5 of these did not gain MACRA
credit as two had colonoscopies completed at an outside facility and three had completed
Cologuard and the provider did not manually document them in the EMR Dashboard.
Other places for documentation include the “History of Present Illness” and “Discussion”
sections of the note along with the “Outside Documents” section of the EMR. Nine patients who
had completed screening had this documented in the “History of Present Illness” section of the
note. Of these nine patients, only two had then been manually entered to receive MACRA credit.
Three patients had screening completion documented in the “Discussion” section of the note.
One of these results had been manually entered into the EMR Dashboard by the provider. In
addition, five patients had screening completed at outside facilities. These results were entered
into the “Outside Documents” section of the EMR. Three of these were completed colonoscopies
while the other two were Cologuard tests. Only two of the five had been manually entered into
the EMR Dashboard, meaning the other three did not receive MACRA credit.
Colorectal cancer screening was not completed by 20 of the patients even though it was
ordered by the provider. Colonoscopy was ordered for 15 of these patients and Cologuard was
ordered for the remaining five patients. The reason screening was not completed was only
documented for one of the 20 patients as “patient refused.” Providers had also recommended
colorectal cancer screening to five additional patients, but the patients had refused to have this
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ordered. Reason for refusal was not included in the documentation. In total, 67 of the 84 ordered
colonoscopies were completed and five of the 11 ordered Cologuard tests were completed.
After presenting these data to the two providers who attended the meeting, strategies were
discussed to improve colorectal cancer screening rates and documentation of colorectal cancer
screening completion. Three strategies were discussed during the meeting: delegate a clinic
support staff to identify scheduled patients who need screening, have the provider document
when screening is due on the patient’s problem list, and add an alert on the patient “dashboard”
to provide an immediate alert when screening is due. The providers believed these strategies
could be easily implemented and will bring these options to their next provider meeting.
Discussion
The American Cancer Society (2019) found that as of 2019, 67.6% of people between the ages
of 50 to 75 in Kentucky had undergone colorectal cancer screening. The results of this chart
review were similar as 61% of the patients in this urban primary care clinic had completed
colorectal cancer screening. However, it was determined that this clinic’s colorectal cancer
screening rate was below the national goal of 80%.
The results did not yield statistical significance in analyzing demographic variables and
provider screening rates. It was determined that screening rates within the clinic are higher than
what is documented to meet MACRA compliance. Therefore, providers are not receiving credit
for some patients who have completed colorectal cancer screening. It also determined that this
was due to error in documentation.
The USPTF recommends FIT testing as a tier 1 colorectal cancer screening detection test (Rex
et al., 2017). Despite this recommendation, providers ordered Cologuard as a colorectal cancer
detection test. Cologuard is not currently recommended as a first-tier test for colorectal cancer
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detection. FIT testing was not ordered for any of the 120 patients whose charts were reviewed.
Of the 84 patients who had colonoscopy ordered 67 of these patients underwent screening
colonoscopy while only five of the 11 patients who had Cologuard screening ordered completed
this testing.
Finally, the literature review showed that providers perceive barriers to colorectal cancer
screening to be at the patient level (American Cancer Society, 2019). However, screening rates
can be increased by 20% when recommended by providers (Knight et al., 2015). While the chart
review revealed that some patients did not complete the ordered and recommended colorectal
cancer screening, it was also determined that in some cases there was no documentation of the
provider recommending colorectal cancer screening. This supports the idea that barriers occur
both at the provider and patient level.
The meeting with the providers led to the discussion of potentially delegating clinic support
staff to identify scheduled patients who need screening. The review of literature indicated that
implementing a clinic facilitator improves the ordering process for screening and increases
colorectal cancer screening rates (Weiner et al., 2017). The providers also discussed adding an
alert on the patient “dashboard” to provide an immediate alert when screening is due. This
coincides with the literature which has shown that implementation of an EMR alert system
increases screening rates (Guiriguet et al., 2016).
Implications
It was determined that providers did not order screening for all patients who satisfy colorectal
cancer screening criteria. Additionally, Cologuard testing was ordered rather than FIT testing.
These results suggest that provider education regarding colorectal cancer screening may be
indicated. This education should include both patient screening guidelines and recommendations
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on modes of screening. More research is needed to determine the benefit of provider education
regarding colorectal cancer screening. It would be beneficial to determine if rates of screening
increase within this primary care clinic after this information was presented to providers.
It was also determined that the clinic’s EMR was a barrier to determining if colorectal cancer
screening was completed and in gaining MACRA credit. Clinic policies should be developed in
order to adopt standard documentation of colorectal cancer screening completion. This in turn
would increase MACRA credit for providers at this urban primary care clinic.
Limitations
There are several limitations in this project. Patient results were reviewed over the last 10
years. However, provider notes in the current EMR were only available for the past 5 years
making it possible for screening to be unaccounted for if completion was not manually
documented in the current EMR.
A second limitation is due to the possibility that documentation can be completed in a way that
shows colorectal cancer screening was completed when in fact it had not been. If the provider
ordered a colorectal cancer screening test and the patient does not complete the test, but the order
is manually completed in the EMR, the patient appears to meet screening compliance based on
MACRA guidelines. This was found to have happened in two of the 120 charts reviewed. This
finding can have multiple implications. First, when reviewing the chart, it appears to the provider
that the patient has completed colorectal cancer screening when they actually have not. This may
cause the provider to not order screening even though it is indicated. This can also cause
provider screening rates to appear higher than they actually are.
A final limitation was that only two of the six providers were able to attend the provider
presentation following the chart review. One of the six providers had left the clinic and the other
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three providers were not available at the time of the meeting. Had all providers been present
more progress may have been made in determining solutions to the results of the chart review.
Conclusion
The purpose of this project was to determine screening rates and documentation mechanisms
for colorectal cancer in an urban primary care practice, to determine how many patients
completed the screening, and to present findings to the practice providers along with exploring
ways to increase screenings. An additional purpose of this project was to determine and identify
patient demographics which can impact rates of screening. The rate of screening was lower than
the national goal of 80%. However, it was determined that there was not a statistical difference in
screening rates based on gender, race, or location of residence. There was also not a statistical
difference in rates of screening between providers or between physicians and nurse practitioners.
It was also determined that colonoscopy and Cologuard were the only screening methods ordered
within in this clinic, even though FIT testing is the first-tier recommendation for colorectal
cancer detection. Providers are screening more patients than they are receiving credit for in terms
of MACRA compliance. Future benefit may be seen by completing provider education and
repeating the chart review to determine the effect that provider education has on rates of
colorectal cancer screening.
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Appendix A
Demographic Variables
Age
Gender
Race
Location of Residency
Colorectal Cancer Screening Status
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Table 1. Gender Screening Completed

Screening Completed
No
Gender

F

Count
% within Screening Completed

M

Count
% within Screening Completed

Total

Count
% within Screening Completed

Yes

Total

31

41

72

66.0%

56.2%

60.0%

16

32

48

34.0%

43.8%

40.0%

47

73

120

100.0%

100.0%

100.0%

Chi-Square Tests
Asymptotic
Value
Pearson Chi-Square

df

Continuity Correction
Likelihood Ratio

Exact Sig. (2-

Exact Sig. (1-

sided)

sided)

sided)

a

1

.285

.771

1

.380

1.152

1

.283

1.143
b

Significance (2-

Fisher's Exact Test
N of Valid Cases

.342
120

a. 0 cells (0.0%) have expected count less than 5. The minimum expected count is 18.80.
b. Computed only for a 2x2 table
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.190

Table 2. Race Screening Completed

Screening Completed
No
Race

Black

Count
% within Screening Completed

Hispanic

Total

34

55

44.7%

46.6%

45.8%

2

5

7

4.3%

6.8%

5.8%

24

34

58

51.1%

46.6%

48.3%

47

73

120

100.0%

100.0%

100.0%

Count
% within Screening Completed
Count
% within Screening Completed

Chi-Square Tests
Asymptotic
Significance (2Value

df

sided)

a

2

.790

Likelihood Ratio

.485

2

.785

N of Valid Cases

120

Pearson Chi-Square

.471

a. 2 cells (33.3%) have expected count less than 5. The minimum expected
count is 2.74.
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Total

21

Count
% within Screening Completed

White

Yes

Table 3. Distance Screening Completed

Screening Completed
No
Distance

1

Yes

Count

43

63

106

91.5%

86.3%

88.3%

4

10

14

8.5%

13.7%

11.7%

47

73

120

100.0%

100.0%

100.0%

% within Screening Completed
2

Count
% within Screening Completed

Total

Count
% within Screening Completed

Total

Chi-Square Tests
Asymptotic
Value

df

Significance (2-

Exact Sig. (2-

Exact Sig. (1-

sided)

sided)

sided)

a

1

.388

Continuity Correction

.328

1

.567

Likelihood Ratio

.775

1

.379

Pearson Chi-Square

.747
b

Fisher's Exact Test
N of Valid Cases

.562
120

a.

0 cells (0.0%) have expected count less than 5. The minimum expected count is 5.48.

b.

Computed only for a 2x2 table

29

.288

Table 4. Screening Rates by Provider
Screening Completed
No
Provider

1

Count
% within Screening Completed

2

Count
% within Screening Completed

4

5

Count
% within Screening Completed

Total

20

12.8%

19.2%

16.7%

7

13

20

14.9%

17.8%

16.7%

10

10

20

21.3%

13.7%

16.7%

8

12

20

17.0%

16.4%

16.7%

5

15

20

10.6%

20.5%

16.7%

11

9

20

23.4%

12.3%

16.7%

47

73

120

100.0%

100.0%

100.0%

Count
% within Screening Completed

6

14

Count
% within Screening Completed

Count
% within Screening Completed

Chi-Square Tests
Asymptotic
Significance (2Value
Pearson Chi-Square
Likelihood Ratio
N of Valid Cases

df

sided)

a

5

.344

5.679

5

.339

5.631

120

a. 0 cells (0.0%) have expected count less than 5. The minimum expected
count is 7.83.
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Total

6

Count
% within Screening Completed

3

Yes

Group Statistics
Screening Completed
Age

N

Mean

Std. Deviation

Yes

73

58.03

5.689

No

47

60.15

6.014

Independent Samples Test
Levene's Test for Equality of Variances

F
Age

Sig.

Equal variances assumed

.472

Equal variances not assumed

31

.493

Table 5. Screening Rates by Provider Type

Screening Completed
No
Provider type

1.00

Yes

Count
% within Screening

Total

21

39

60

44.7%

53.4%

50.0%

26

34

60

55.3%

46.6%

50.0%

47

73

120

100.0%

100.0%

100.0%

Completed
2.00

Count
% within Screening
Completed

Total

Count
% within Screening
Completed

Chi-Square Tests
Asymptotic
Value

df

Significance (2-

Exact Sig. (2-

Exact Sig. (1-

sided)

sided)

sided)

a

1

.350

Continuity Correction

.560

1

.454

Likelihood Ratio

.876

1

.349

Pearson Chi-Square

.874
b

Fisher's Exact Test
N of Valid Cases

.455
120

a. 0 cells (0.0%) have expected count less than 5. The minimum expected count is 23.50.
b. Computed only for a 2x2 table

32

.227

